Journal of the American Academy of Dermatology最新文献_第4页

Ethics of Ambient Documentation.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-11 DOI: 10.1016/j.jaad.2025.03.007

Shae Chambers, Ameya Gangal, Benjamin Stoff

引用次数: 0

Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-11 DOI: 10.1016/j.jaad.2025.03.008

Melinda Gooderham, Sonja Molin, Robert Bissonnette, Margitta Worm, Marie-Noëlle Crépy, Luca Stingeni, Richard B Warren, Sibylle Schliemann, Marie-Louise Schuttelaar, Silvia Ferrucci, Esther Serra-Baldrich, Jonathan I Silverberg, Cherry Lou Balita-Crisostomo, Marie Louise Oesterdal, Ursula Plohberger, Tove Agner

{"title":"Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.","authors":"Melinda Gooderham, Sonja Molin, Robert Bissonnette, Margitta Worm, Marie-Noëlle Crépy, Luca Stingeni, Richard B Warren, Sibylle Schliemann, Marie-Louise Schuttelaar, Silvia Ferrucci, Esther Serra-Baldrich, Jonathan I Silverberg, Cherry Lou Balita-Crisostomo, Marie Louise Oesterdal, Ursula Plohberger, Tove Agner","doi":"10.1016/j.jaad.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.008","url":null,"abstract":"Background: There are no topical treatments that have been specifically developed and approved for moderate to severe Chronic Hand Eczema (CHE).Objective: To evaluate the long-term safety and efficacy of delgocitinib cream 20 mg/g as needed for 36 weeks in adults with CHE.Methods: In phase 3 open-label DELTA 3 (NCT04949841), patients who completed the 16-week(W) treatment period in DELTA 1 and 2 were treated on an as-needed basis with twice-daily delgocitinib for 36 weeks (n=801). Patients with Investigator's Global Assessment for CHE (IGA-CHE)≥2 received treatment until IGA-CHE≤1 was achieved. Primary endpoint was number of treatment-emergent adverse events (AEs). Key secondary endpoints were IGA-CHE 0/1 and ≥75%/≥90% improvement in Hand Eczema Severity Index (HECSI-75/90) scores.Results: Delgocitinib was well tolerated (n=801; R=231.1; PYO=535.7), with most frequent AEs being COVID-19 and nasopharyngitis. DELTA 3 baseline IGA-CHE 0/1 (24.6%), HECSI-75/HECSI-90 (51.8%/31.8%) were maintained to W36 (30.0% and 58.6%/36.6%, respectively) among delgocitinib-treated patients in the parent trials. Among those previously treated with cream vehicle, corresponding response rates improved from DELTA 3 baseline (9.1% and 23.7%/12.0%, respectively) to W36 (29.5% and 51.5%/35.7%).Limitations: Open-label trial.Conclusion: Delgocitinib cream treatment was well-tolerated and efficacious in maintaining disease control in CHE patients up to 52 weeks.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: a retrospective cohort study.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-11 DOI: 10.1016/j.jaad.2025.03.012

Daniela Frankel, Karla Valdes-Morales, Mara D Trifoi, Stephanie K Lin, Annika M Deitermann, Manisha Banala, Esther Zhang, Nicole Easo, Marissa Lubeck, Dylan Haynes, Daniel Lewis, Shannon T Nugent, Jeremy R Etzkorn, Neha N Jariwala, Junqian Zhang, Joanna L Walker, H William Higgins, Joseph F Sobanko, Cerrene N Giordano, Parnaz Daneshpajouhnejad, Mitul Modi, Ines C Lin, Benjamin Chang, Jason Wink, Giorgos Karakousis, John Miura, Christopher J Miller

{"title":"Mohs micrographic surgery reduces the risk of reconstruction with positive margins, repeat surgeries, and time to definitive reconstruction compared to conventional excision of hand and foot melanomas: a retrospective cohort study.","authors":"Daniela Frankel, Karla Valdes-Morales, Mara D Trifoi, Stephanie K Lin, Annika M Deitermann, Manisha Banala, Esther Zhang, Nicole Easo, Marissa Lubeck, Dylan Haynes, Daniel Lewis, Shannon T Nugent, Jeremy R Etzkorn, Neha N Jariwala, Junqian Zhang, Joanna L Walker, H William Higgins, Joseph F Sobanko, Cerrene N Giordano, Parnaz Daneshpajouhnejad, Mitul Modi, Ines C Lin, Benjamin Chang, Jason Wink, Giorgos Karakousis, John Miura, Christopher J Miller","doi":"10.1016/j.jaad.2025.03.012","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.012","url":null,"abstract":"Background: Hand and foot melanomas (HFM) have increased risk for positive margins after conventional excision (CE). Mohs micrographic surgery (MMS) may improve margin clearance prior to reconstruction. Rates of reconstruction with positive margins have not been compared after CE versus MMS for HFM.Objective: To compare rates of reconstruction with positive margins after CE or MMS of HFM.Methods: In situ and invasive melanomas of hands and feet treated with CE or MMS with MART-1 immunostaining between 1994-2023 were identified from an academic center. The primary outcome was rate of reconstruction with positive margins after CE vs MMS. Secondary outcomes were repeat excision and time to definitive reconstruction after CE vs MMS.Results: Of 269 HFM, 180 (66.91%) were treated with MMS versus 89 (33.09%) with CE. Reconstruction with positive margins after initial excision was significantly more likely after CE (20.22%) versus MMS (0%) [p<0.001]. Compared to MMS, CE had higher rates of repeat excisions (20.22% vs. 1.67%) [p<0.001] and longer mean time to definitive reconstruction (11.35 vs. 1.44 days) [p<0.001].Limitations: Single site, retrospective design.Conclusion: Compared to MMS, CE of HFMs has higher rates of reconstruction with positive margins, repeat surgeries, and a longer time to definitive reconstruction.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.03.006

Kelly G Paulson, Song Y Park, Shailender Bhatia, Daniel S Hippe, Paul Nghiem

{"title":"Improved survival at the population level for patients with advanced Merkel cell carcinoma following availability of immunotherapy.","authors":"Kelly G Paulson, Song Y Park, Shailender Bhatia, Daniel S Hippe, Paul Nghiem","doi":"10.1016/j.jaad.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.03.006","url":null,"abstract":"Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer with poor survival rates. Immune checkpoint inhibitors (ICIs) were FDA-approved for advanced MCC in 2017, but their real-world survival impact remains unclear.Objective: Evaluate whether ICI introduction in the US corresponded with improved survival.Methods: This cohort study analyzed SEER data for MCC patients diagnosed from 2010 to 2021, grouped by 3-year periods, to calculate 2-year overall and relative survival.Results: For 453 patients with metastatic MCC, 2-year relative survival improved from 23% (2010-2012) to 37% (2013-2015), 42% (2016-2018), and 54% (2019-2021) (p < 0.001). Median overall survival also increased from 9 to 16 months among these patients. In 4,786 MCC patients overall, 2-year relative survival rose from 73% (2010-2012) to 81% (2019-2021) (p = 0.004), while overall survival improved from 67% to 72% (p = 0.012).Limitations: SEER lacks case-level data to link ICI treatment directly to survival, although ICIs represent the major recent treatment advance for MCC.Conclusions: The introduction of ICIs aligns with a >2-fold increase in survival for advanced MCC patients at the population level, translating to ∼220 fewer deaths per year in the U.S.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and outcomes of dipeptidyl peptidase-4 inhibitor-associated pemphigus patients: A retrospective analysis of 66 cases.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.01.103

Gaurav N Pathak, Anushka Pande, Babar K Rao

引用次数: 0

Disease severity and pruritus treatment outcomes in prurigo nodularis: A systematic review of randomized-controlled trials.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.03.009

Ryan S Q Geng, Siddhartha Sood, Jihad Waked, Rayyan Mahmood, Khalad Maliyar, Muskaan Sachdeva, Abrahim Abduelmula, Jensen Yeung, Asfandyar Mufti

引用次数: 0

Discount pharmacies may save patients significant money on androgenetic alopecia medications compared to both traditional pharmacies and direct-to-consumer companies.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.02.089

Manas Ranpariya, Jules B Lipoff

引用次数: 0

In-transit melanoma metastases: Evaluation and Management for the Dermatologist.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-10 DOI: 10.1016/j.jaad.2025.03.005

Anagha Bangalore Kumar, James W Jakub, Scott C Lester, Svetomir N Markovic, Christian L Baum

引用次数: 0

Navigating patient access to treatment: a focus on pharmaceutical drug samples.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-08 DOI: 10.1016/j.jaad.2025.01.102

Melissa C Leeolou, Justin L Jia, Kavita Y Sarin

引用次数: 0

Evaluating Patient's Ability to Detect Changes in Hair Density Using Standardized Global Scalp Photography: A Cross-Sectional Study.

IF 12.8 1区医学

Journal of the American Academy of Dermatology Pub Date : 2025-03-08 DOI: 10.1016/j.jaad.2025.03.010

Christina S Oh, Nnaemeka Anyanwu, Michael G Buontempo, Deesha Desai, Ambika Nohria, Jerry Shapiro, Kristen Lo Sicco

引用次数: 0